JP5563452B2 - 一酸化炭素による胃潰瘍の予防 - Google Patents

一酸化炭素による胃潰瘍の予防 Download PDF

Info

Publication number
JP5563452B2
JP5563452B2 JP2010517503A JP2010517503A JP5563452B2 JP 5563452 B2 JP5563452 B2 JP 5563452B2 JP 2010517503 A JP2010517503 A JP 2010517503A JP 2010517503 A JP2010517503 A JP 2010517503A JP 5563452 B2 JP5563452 B2 JP 5563452B2
Authority
JP
Japan
Prior art keywords
corm
nsaid
substituted
medicament
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010517503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534236A5 (OSRAM
JP2010534236A (ja
Inventor
ロドリゲス，サンドラ，エスィ．
デー． セイシャス，ジョアン
グレイロ，ブルーノ
ペレイラ，ヌノ，ミゲル，ペナチョ
セー． ロマン，カルロス
ハース，ウェルナー，エー．
デ ソウサ ゴンサウベス，イサベル，マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfama Investigacao e Desenvolvimento de Produtos Farmaceut Lda
Original Assignee
Alfama Investigacao e Desenvolvimento de Produtos Farmaceut Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfama Investigacao e Desenvolvimento de Produtos Farmaceut Lda filed Critical Alfama Investigacao e Desenvolvimento de Produtos Farmaceut Lda
Publication of JP2010534236A publication Critical patent/JP2010534236A/ja
Publication of JP2010534236A5 publication Critical patent/JP2010534236A5/ja
Application granted granted Critical
Publication of JP5563452B2 publication Critical patent/JP5563452B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010517503A 2007-07-24 2008-07-24 一酸化炭素による胃潰瘍の予防 Expired - Fee Related JP5563452B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95165007P 2007-07-24 2007-07-24
US60/951,650 2007-07-24
PCT/IB2008/001945 WO2009013612A1 (en) 2007-07-24 2008-07-24 Prevention of gastric ulcery by carbon monoxide

Publications (3)

Publication Number Publication Date
JP2010534236A JP2010534236A (ja) 2010-11-04
JP2010534236A5 JP2010534236A5 (OSRAM) 2012-11-22
JP5563452B2 true JP5563452B2 (ja) 2014-07-30

Family

ID=40010478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517503A Expired - Fee Related JP5563452B2 (ja) 2007-07-24 2008-07-24 一酸化炭素による胃潰瘍の予防

Country Status (5)

Country Link
US (3) US20110038955A1 (OSRAM)
EP (1) EP2182961B1 (OSRAM)
JP (1) JP5563452B2 (OSRAM)
AT (1) ATE555795T1 (OSRAM)
WO (1) WO2009013612A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
CA2475209A1 (en) 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070065485A1 (en) * 2003-08-04 2007-03-22 Motterlini Roberto A Therapeutic delivery of carbon monoxide
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US9512156B2 (en) 2010-03-08 2016-12-06 University Of Zurich Carbon monoxide releasing rhenium compounds for medical use
WO2012075244A2 (en) * 2010-12-01 2012-06-07 Virginia Commonwealth University Use of hemoglobin effectors to increase the bioavailability of therapeutic gases
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
JP6564785B2 (ja) * 2014-03-21 2019-08-21 ユニベルシテ パリ−エスト クレテイユ ヴァル ド マルヌＵｎｉｖｅｒｓｉｔｅ Ｐａｒｉｓ−Ｅｓｔ Ｃｒｅｔｅｉｌ Ｖａｌ Ｄｅ Ｍａｒｎｅ フマレート−ｃｏ−放出分子ハイブリッド、炎症性疾患又は心血管疾患の治療におけるそれらの使用及びそれらの調製方法
JP2018145248A (ja) * 2017-03-02 2018-09-20 国立大学法人京都大学 無限配位高分子（ＩＣＰｓ）を用いた一酸化炭素放出材料
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
WO2022055991A1 (en) * 2020-09-08 2022-03-17 The Brigham And Women's Hospital, Inc. Therapeutic carbon monoxide formulations
WO2025254524A1 (en) 2024-06-05 2025-12-11 Rijksuniversiteit Groningen Carbon monoxide releasing therapeutic compounds and methods, products and uses related thereto

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065250A (en) * 1960-05-13 1962-11-20 Hercules Powder Co Ltd Nitrile-metal carbonyl complexes
US4569214A (en) * 1983-09-14 1986-02-11 Yang Yaw Kuen Push button security lock
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
CA2475209A1 (en) * 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
EA200500062A1 (ru) * 2002-06-21 2005-06-30 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Фармацевтическое применение оксида азота, гемоксигеназы-1 и продуктов деградации гема
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
GB0601394D0 (en) * 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP2010525055A (ja) * 2007-04-24 2010-07-22 アルファーマ−インベスティガシオ エ デセンボルビメント デ プロデュトス ファルマセウティコス エレデア． 一酸化炭素による感染症の処置

Also Published As

Publication number Publication date
US20140212514A1 (en) 2014-07-31
US20110038955A1 (en) 2011-02-17
WO2009013612A1 (en) 2009-01-29
US20170157168A1 (en) 2017-06-08
ATE555795T1 (de) 2012-05-15
JP2010534236A (ja) 2010-11-04
EP2182961A1 (en) 2010-05-12
EP2182961B1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
JP5563452B2 (ja) 一酸化炭素による胃潰瘍の予防
KR102568384B1 (ko) 융합된 비시클릭 sGC 자극제
JP6075903B2 (ja) Ｐｆｋｆｂ２阻害剤および抗癌治療法としての使用方法
Yang et al. C-lysine conjugates: pH-controlled light-activated reagents for efficient double-stranded DNA cleavage with implications for cancer therapy
JP2010525055A (ja) 一酸化炭素による感染症の処置
US20160106722A1 (en) Human therapeutic agents
CN1228703A (zh) 用于治疗由自由基引发的疾病的螯合剂及其金属螯合物
EP4086250B1 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CA3012001A1 (en) Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
CA3006764A1 (en) Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
JP2022062115A (ja) ｓＧＣ刺激剤のリンプロドラッグ
Reetu et al. Recent Advances in Synthesis and Medicinal Evaluation of 1, 2‐Benzothiazine Analogues
Chawla et al. Chemical modifications of ketoprofen (NSAID) in search of better lead compounds: A Review of literature from 2004-2016
CA2636042A1 (en) Lanthionine-related compounds for the treatment of inflammatory diseases
JPWO2012014805A1 (ja) 一酸化窒素生成調節剤
AU2017247008A1 (en) Isoflavonoid composition with improved pharmacokinetics
EP3554488A2 (en) Use of sgc stimulators for the treatment of esophageal motility disorders
AU2017235350A1 (en) Combination therapy for proliferative diseases
JP2014534227A5 (OSRAM)
WO2006099685A1 (en) Method for the prophylaxis or treatment of carcinomas
JP2005132766A (ja) 光動力学的癌治療薬
AU5430899A (en) Drug targeting
Tallon Synthesis of imidazole schiff base ligands, their silver (I) complexes and their activities against candida albicans
Frija et al. 1, 2‐Benzisothiazole 1, 1‐Dioxide (Saccharinate)‐Based Compounds Synthesis, Reactivity and Applications
WO2006099677A1 (en) Metal complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140612

R150 Certificate of patent or registration of utility model

Ref document number: 5563452

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees